Abstract: The present invention relates to use of the compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof in the manufacture of a medicament or pharmaceutical composition for preventing, treating or lessening POD,

Abstract: The present invention relates to a method of treating, preventing, or lessening postoperative cognitive dysfunction (POCD) in a subject in need thereof, the method comprising the step of administering to the subject a therapeutically effective amount of a compound of Formula I or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof,

Abstract: A device for selectively providing an odor-rich environment includes a housing and a cover. The housing includes a central cavity and a plurality of chambers configured to store a predefined fragrance therein and having a respective outlet formed on an outer wall of the housing. The cover includes an exterior surface having at least one vent formed on the exterior surface. The exterior surface includes an interior sidewall and an exterior sidewall forming an inner chamber that slidably engages the housing such that the cover is configured to move between an open position and a closed position. Responsive to the cover being in the open position, the at least one vent is generally adjacent to the outlet of at least one of the plurality of chambers of the housing. The odor-rich environment can assist in preventing and/or treating postoperative delirium (POD) postoperative cognitive dysfunction (POCD), and/or pain in a subject.

Abstract: A device for selectively providing an odor-rich environment includes a housing and a cover. The housing includes a central cavity and a plurality of chambers configured to store a predefined fragrance therein and having a respective outlet formed on an outer wall of the housing. The cover includes an exterior surface having at least one vent formed on the exterior surface. The exterior surface includes an interior sidewall and an exterior sidewall forming an inner chamber that slidably engages the housing such that the cover is configured to move between an open position and a closed position. Responsive to the cover being in the open position, the at least one vent is generally adjacent to the outlet of at least one of the plurality of chambers of the housing. The odor-rich environment can assist in preventing and/or treating postoperative delirium (POD) postoperative cognitive dysfunction (POCD), and/or pain in a subject.

Abstract: A device for selectively providing an odor-rich environment includes a housing and a cover. The housing includes a central cavity and a plurality of chambers configured to store a predefined fragrance therein and having a respective outlet formed on an outer wall of the housing. The cover includes an exterior surface having at least one vent formed on the exterior surface. The exterior surface includes an interior sidewall and an exterior sidewall forming an inner chamber that slidably engages the housing such that the cover is configured to move between an open position and a closed position. Responsive to the cover being in the open position, the at least one vent is generally adjacent to the outlet of at least one of the plurality of chambers of the housing. The odor-rich environment can assist in preventing and/or treating postoperative delirium (POD) postoperative cognitive dysfunction (POCD), and/or pain in a subject.

Abstract: Disclosed herein is a method for administering compositions. Also disclosed are kits comprising a compound of formula (I) to (V), or an enantiomer, an analog, a derivative, an isomer, prodrug, or a pharmaceutically acceptable salt thereof, for use in temporal proximity to anesthesia. The methods, compositions and kits provided herein can be used for reducing anesthesia-induced neurotoxicity and post-operative cognitive dysfunction (POCD) in a subject.

Abstract: Methods for the use of uncompetitive NMDA receptor antagonist(s) in inhalational anesthesia are provided herein.

Abstract: The present invention relates to the treatment and prophylactic prevention of Alzheimer's disease. More specifically, the present invention relates to methods and compositions for reducing production of ? amyloid by reducing or preventing the binding of amyloid precursor protein (APP) to an X11 adaptor protein. Also provided are methods for identifying molecules that modulate APP-X11 binding.